GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of someone explain endpoint to me like I have not read a paper in years — 32 comments in the full submission. View in context.
1.6k
c/trialwatch·submitted 2 years ago by u/hsa_math

someone explain endpoint to me like I have not read a paper in years

Readoutbranch of 4 comments

I have had 18 orders now and I keep a table, so here is the honest summary rather than a vibe. Material has been consistent. Communication has not. Shipping has varied by about 38 days on nominally the same lane, which matters more in summer than in February. The independent number came back 98.4% against a claimed…

Read the full submission and all 32 comments →

This branch

4 comments, started 2 years ago
u/cloudy_vial_carol92 points·2 years ago

dropout handling matters, especially on GI-heavy populations

replysharereportpermalink
u/hsa_mathOP65 points·2 years ago

dropout handling matters, especially on GI-heavy populations

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

replysharereportpermalink
u/hub_opssite staff16 points·2 years ago

dropout handling matters, especially on GI-heavy populations Counter-anecdote: opposite result, same dose.

Adding to this: hazard ratio is doing more work than the comment implies.

replysharereportpermalink
u/sofia_ferreira5 points·2 years ago

absolute risk reduction, not relative risk reduction, that is how you decide

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →